Celgene’s Alkeran Extends Life in Eye-Cancer Patients in Study

Melphalan, the active ingredient in Celgene Corp. (CELG)’s Alkeran, helped patients live longer after cancer had spread from their eyes to their livers, according to a study to be presented today at the European Multidisciplinary Cancer Congress in Stockholm.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.